2024 Guide for the Primary Prevention of Stroke:A Guideline From the American Heart Association/American Stroke Association
Stroke 55:e344-e424, Bushnell,C.,et al, 2024
Antiplatelet and Anticoagulant Agents for Secondary Prevention of Thromboembolic Events in People with Antiphospholipid Syndrome
Stroke 49:e41-e42, Bala, M.M.,et al, 2018
Diagnosis and Management of the Antiphospholipid Syndrome
BMJ 340:1125-1132, Cohen,D., et al, 2010
Management of Antiphospholipid Antibody Syndrome, A Systematic Review
JAMA 295:1050-1057, Lim,W.,et al, 2006
Antiphospholipid Antibodies in Cerebral Ischemia
Stroke 22:750-753, Montalban,J.,et al, 1991
Amaurosis Fugax Associated with Antiphospholipid Antibodies
Ann Neurol 25:228-232, Digre,K.B.,et al, 1989
Emergency Administration of Abciximab for Treatment of Patients With Acute Ischemic Stoke: Results of an International Phase III Trial: Abciximab in Emergency Treatment of Stroke Trial (AbESTT-II)
Stroke 39:89-99, Adams,H.P.,Jr.,et al, 2008
Agressive Therapy With Intravenous Abciximab and Intra-Arterial rtPA and Additional PTA/Stenting Improves Clinical Outcome in Acute Vertebrobasilar Occlusion
Stroke 36:1160-1165, Eckert,B.,et al, 2005
Reversal of Dense Signs Predicts Recovery in Acute Ischemic Stroke
Stroke 36:e2490-e2492, Mandava,P. &Kent,T.A., 2005
Anticoagulants and Antiplatelet Agents in Acute Ischemic Stroke
Neurol 59:13-22, Coull,B.M.,et al, 2002
Rescue Treatment with Abciximab in Acute Ischemic Stroke
Neurol 56:1585-1587, Lee,K.Y.,et al, 2001
Risk of Stroke Associated With Abciximab Among Patients Undergoing Percutaneous Coronary Intervention
JAMA 286:78-82, Akkerhuis,K.M.,et al, 2001